Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | ACE | P12821 | 9/20 | 0.67 |
| ▸ | MME | P08473 | 7/20 | 0.67 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.55 |
| ▸ | CPA1 | P15085 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP3 | P08254 | 1/20 | 0.53 |
| ▸ | FPR2 | P25090 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12863002 | 1.00 | NPSR1 (0.69) | NPSR1ACEMMEACE2L3MBTL1 | |
| SCHEMBL17468460 | 1.00 | NPSR1 (0.69) | NPSR1ACEMMEACE2L3MBTL1 | |
| SCHEMBL683352 | 0.89 | NPSR1 (0.55) | NPSR1ACEMMEACE2L3MBTL1 | |
| SCHEMBL684246 | 0.89 | NPSR1 (0.55) | NPSR1ACEMMEACE2L3MBTL1 | |
| SCHEMBL30587429 | 0.87 | ACE (0.59) | NPSR1ACEMMEACE2L3MBTL1 | |
| SCHEMBL2550703 | 0.87 | FOLH1 (0.61) | NPSR1ACEMMEACE2NAALAD2 | |
| SCHEMBL2550705 | 0.87 | FOLH1 (0.61) | NPSR1ACEMMEACE2NAALAD2 | |
| SCHEMBL10408617 | 0.87 | ACE (0.68) | NPSR1ACEMMEACE2L3MBTL1 | |
| SCHEMBL12862963 | 0.87 | NPSR1 (0.54) | NPSR1ACEMMEACE2MMP1 | |
| SCHEMBL13886186 | 0.86 | NPSR1 (0.54) | NPSR1ACEMMEACE2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854772-A | Analogue of endomorphin and adenine conjugated peptide with analgesic activity and synthesis method thereof | 中国人民解放军空军军医大学 | 2023-10-10 | — | — | CN | claimed |
| CN-115340468-B | (R) -deuterated phenylalanine derivative and preparation method thereof | 西南大学 | 2023-10-24 | — | — | CN | disclosed |
| CN-116854772-A | Analogue of endomorphin and adenine conjugated peptide with analgesic activity and synthesis method thereof | 中国人民解放军空军军医大学 | 2023-10-10 | — | — | CN | disclosed |
| EP-3565573-B1 | PAC1 RECEPTOR AGONISTS (MAXCAPS) AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-115340468-A | (R) -deuterated phenylalanine derivative and preparation method thereof | 西南大学 | 2022-11-15 | — | — | CN | disclosed |
| US-11186622-B2 | PAC1 receptor agonists (MAXCAPS) and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-30 | — | — | US | disclosed |
| US-10905736-B2 | Ezetimibe-associated ApoA-I mimetic peptides showing enhanced synergism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-02 | — | — | US | disclosed |
| US-10844102-B2 | Peptides, compositions, and methods for stimulating subcutaneous adipogenesis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-24 | — | — | US | disclosed |
| US-10766927-B2 | Peptides that stimulate subcutaneous adipogenesis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190322718-A1 | PAC1 RECEPTOR AGONISTS (MAXCAPS) AND USES THEREOF | THE UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2019-10-24 | — | — | US | disclosed |
| US-20020151546-A1 | HIV protease inhibitors based on amino acid derivatives | TAIMED BIOLOGICS, INC. (TW) | 2002-10-17 | — | — | US | disclosed |
| WO-2002064551-A1 | HIV PROTEASE INHIBITORS BASED ON AMINO ACID DERIVATIVES | PHARMACOR INC. (CA) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002015923-A1 | ORALLY ADMINISTERED PEPTIDES TO AMELIORATE ATHEROSCLEROSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-02-28 | — | — | WO | disclosed |
| US-5202312-A | Antiarthritic agents, antiallergens, antidiabetic agents | TANABE SEIYAKU CO., LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| EP-0372818-A2 | Imidazole-containing peptide and preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1990-06-13 | — | — | EP | disclosed |
| US-4863903-A | RENIN ENZYME INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
| US-4719288-A | HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1988-01-12 | — | — | US | disclosed |
| US-4613676-A | PEPTIDES | CIBA-GEIGY CORPORATION (US) | 1986-09-23 | — | — | US | disclosed |
| EP-0144290-A2 | Substituted ethylenediamine derivatives | CIBA-GEIGY AG (CH) | 1985-06-12 | — | — | EP | disclosed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151546-A1 | HIV protease inhibitors based on amino acid derivatives | ANPEP, PEPD, XPNPEP1 | NPSR1 3222/4885ACE 24/4885MME 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.